SpringerProtocols: Abstract: A Method for Helper Virus-Free Production of Adeno-Associated Virus Vectors

A Method for Helper Virus-Free Production of Adeno-Associated Virus Vectors

By: Roy F. Collaco², James P. Trempe²

Abstract

Full Text

Download PDF (227K)

The need for safe and effective gene transfer to mammalian cells and organisms has led many investigators to focus on the defective human parvovirus, adeno-associated virus (AAV), as a gene delivery vehicle. AAV vectors have been used to deliver genes to a wide variety of mammalian cells in culture, as well as to brain (1), retina (2,3), cochlea (4), skeletal muscle (5,6), cardiac muscle (7), liver (8), lung (9,10), central nervous system (11), and skin (12). The success of these preclinical models has led to several ongoing and proposed human clinical trials (13). One of the major limitations of the AAV vector system to date has been the lack of a versatile and robust method of vector preparation. This chapter describes a method for the helper virus-free preparation of AAV vectors. The method circumvents the need for adenovirus (Ad) coinfection and its simplicity makes it amenable for screening multiple AAV vector constructions. To lay the foundation for the development of this and other AAV packaging systems, a brief summary of AAV biology is provided later. More detailed reviews describing AAV and its derived vectors are available in (14 and 15).

Affiliation(s): (2) Department of Biochemistry and Molecular Biology, Medical College of Ohio, Toledo, OH

Book Title: Viral Vectors for Gene Therapy: Methods and Protocols

Series: Methods in Molecular Medicine | Volume: 76 | Pub. Date: Oct-07-2002 | Page Range: 237-254 | DOI: 10.1385/1-59259-304-6:237

Subject: Genetics/Genomics

References

Download References

1.	Ali, R. R. (1996) Gene transfer into the mouse retina mediated by an adenoassociated viral vector. Hum. Mol. Genet. 5, 591–594.

2.	Allen, J. M., Debelak, D. J., Reynolds, T. C., and Miller, A. D. (1997) Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J. Virol. 71, 6816–6822.

3.	Allen, J. M., Halbert, C. L., and Miller, A. D. (2000) Improved adeno-associated virus vector production with transfection of a single helper adenovirus gene, E4orf6. Mol. Ther. 1, 88–95.

4.	Anderson, W. F., Wilson, J. M., Kay, M. A., Bordignon, C., Heard, J. M., and Kaneko, S. (2000) Human gene marker/therapy clinical protocols. Hum. Gene Ther. 11, 1745–1816.

5.	Atchison, R. W., Casto, B. C., and Hammon, W. M. (1965) Adenovirus-associated defective virus particles. Science 194, 754–757.

6.	Berns, K. and Giraud, C. (1996) Biology of adeno-associated virus. Curr. Top. Microbiol. Immunol. 281, 1–23.

7.	Brockstedt, D. G., Podsakoff, G. M., Fong, L., Kurtzman, G., Mueller-Ruchholtz, W., and Engleman, E. G. (1999) Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin. Immunol. 92, 67–75.

8.	Chang, L.-S., and Shenk, T. (1990) The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenovirus and adeno-associated virus promoters. J. Virol. 64, 2103–2109.

9.	Chang, L.-S., Shi, Y., and Shenk, T. (1989) Adeno-associated virus P5 promoter contains an adenovirus E1a-inducible element and a binding site for the major late transcription factor. J. Virol. 63, 3479–3488.

10.	Clark, K. R., Liu, X., McGrath, J. P., and Johnson, P. R. (1999) Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum. Gene Ther. 10, 1031–1039.

11.	Clark, K. R., Voulgaropoulou, F., Fraley, D. M., and Johnson, P. R. (1995) Cell lines for the production of recombinant adeno-associated virus. Hum. Gene Ther. 6, 1329–1341.

12.	Collaco, R. F., Cao, X., and Trempe, J. P. (1999) A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 238, 397–405. <Occurrence Type="DOI"><Handle>10.1016/S0378-1119(99)00347-9</Handle></Occurrence>

13.	Conway, J. E., Zolotukhin, S., Muzyczka, N., Hayward, G. S., and Byrne, B. J. (1997) Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J. Virol. 71, 8780–8789.

14.	Donahue, B. A., McArthur, J. G., Spratt, S. K., Bohl, D., Lagarde, C., Sanchez, L., et al. (1999) Selective uptake and sustained expression of AAV vectors following subcutaneous delivery. J. Gen. Med. 1, 31–42. <Occurrence Type="DOI"><Handle>10.1002/(SICI)1521-2254(199901/02)1:1<31::AID-JGM3>3.0.CO;2-T</Handle></Occurrence>

15.	Duan, D., Yue, Y., Yan, Z., and Engelhardt, J. E (2000) Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J. Clin. Invest. 105, 1573–1587.

16.	Ferrari, E K., Samulski, T., Shenk, T., and Samulski, R. J. (1996) Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70, 3227–3234.

17.	Fisher, K. J., Gao, G.-P., Weitzman, M. D., DeMatteo, R., Burda, J. F., and Wilson, J. M. (1996) Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70, 520–532.

18.	Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., et al. (1997) Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med. 3, 306–312.

19.	Flannery, J. G., Zolotukhin, S., Vaquero, M. I., Lavail, M. M., Muzyczka, N., and Hauswirth, W. W. (1997) Efficient photoreceptor gene expression in vivo by recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA 94, 6916–6921.

20.	Flotte, T. R., Afione, S. A., Conrad, C., McGrath, S. A., Solow, R., Oka, H., et al. (1993) Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc. Natl. Acad. Sci. USA 90, 10,613–10,617.

21.	Gao, G., Qu, G., Burnham, M. S., Huang, J., Chirmule, N., Joshi, B., et al. (2000) Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum. Gene Ther. 11, 2079–2091.

22.	Gao, G.-P., Qu, G., Faust, L. Z., Engdahl, R. K., Xiao, W., Hughes, J. V., et al. (1998) High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum. Gene Ther. 9, 2353–2362.

23.	Grimm, D., Kern, A., Rittner, K., and Kleinschmidt, J. A. (1998) Novel tools for the production and purification of recombinant adeno-associated virus vectors. Hum. Gene Ther. 9, 2745–2760.

24.	Halbert, C. L., Standaert, T. A., Wilson, C.B., and Miller, A. D. (1998) Successful re-administration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during initial exposure. J. Virol. 72, 9795–9805.

25.	Hansen, J., Qing, K., Kwon, H.-J., Mah, C., and Srivastava, A. (2000) Impaired intracellular trafficking of adeno-associated virus type 2 vector limits efficient transduction of murine fibroblasts. J. Virol. 74, 992–996.

26.	Hernandez, Y. I., Wang, J., Kearns, W. G., Loiler, S., Poirier, A., and Flotte, T. R. (1999) Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J. Virol. 73, 8549–8558.

27.	Hoggan, M. D., Blacklow, N. R., and Rowe, W. P. (1966) Studies of small DNA viruses found in various adenovirus preparations. Proc. Natl. Acad. Sci. USA 55, 1457–1461.

28.	Inoue, N., and Russell, D. W. (1998) Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors. J. Virol. 72, 7024–7031.

29.	Janik, J. E., Huston, M. M., Cho, K., and Rose, J. A. (1989) Efficient synthesis of adeno-associated virus structural proteins requires both adenovirus DNA binding protein and VAIRNA. Virology 168, 320–329. <Occurrence Type="DOI"><Handle>10.1016/0042-6822(89)90272-9</Handle></Occurrence>

30.	Janik, J. E., Huston, M. M., and Rose, J. A. (1981) Location of adenovirus genes required for the replication of adenovirus-associated virus. Proc. Natl. Acad. Sci. USA 78, 1925–1929.

31.	Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O’Malley, K. L., et al. (1994) Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8, 148–154.

32.	Kaplitt, M. G., Xiao, X., Samulski, R. J., Li, J., Ojamaa, K., Klein, I. L., et al. (1996) Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. Ann. Thorac. Surg. 62, 1669–1676. <Occurrence Type="DOI"><Handle>10.1016/S0003-4975(96)00946-0</Handle></Occurrence>

33.	Kearns, W. G., Afione, S. A., Fulmer, S. B., Pang, M. C., Erickson, D., Egan, M., et al. (1996) Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther. 9, 748–755.

34.	Kessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., et al. (1996) Gene delivery to skeletal muscle in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA 93, 14,082–14,087.

35.	Kotin, R. (1994) Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum. Gene Ther. 5, 793–801.

36.	Kotin, R., Siniscalco, M., Samulski, R. J., Zhu, X., Hunter, L., Laughlin, C. A., et al. (1990) Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA 87, 2211–2215.

37.	Lalwani, A., Walsh, B., Reilly, P., Carvalho, G., Zolotukhin, S., Muzyczka, N., et al. (1998) Long-term in vivo cochlear transgene expression mediated by recombinant adeno-associated virus. Gene Ther. 5, 277–281.

38.	Laughlin, C. A., Jones, N., and Carter, B. J. (1982) Effect of deletions in adenovirus early region I genes upon replication of adeno-associated virus. J. Virol. 41, 868–876.

39.	Liu, X. L., Clark, K. R., and Johnson, P. R. (1999) Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther. 6, 293–299.

40.	Liu, Y., Santin, A.D., Mane, M., Chiriva-Internati, M., Parham, G.P., Ravaggi, A., et al. (2000) Transduction and utility of the granulocyte-macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus. J. Interfer. Cytokine Res. 20, 21–30.

41.	Malik, P., McQuiston, S. A., Yu, X. J., Pepper, K. A., Krall, W. J., Podsakoff, G. M., et al. (1997) Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line. J. Virol. 71, 1776–1783.

42.	Manning, W. C., Paliard, X., Zhou, S., PatBland, M., Lee, A. Y., Hong, K., et al. (1997) Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J. Virol. 71, 7960–7962.

43.	Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villareal, L., Kurtzman, G., et al. (1998) Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5, 938–945.

44.	Monahan, P. E. and Samulski, R. J. (2000) AAV vectors: Is clinical success on the horizon. Gene Ther. 7, 24–30.

45.	Monahan, P. E., Samulski, R. J., Tazelar, J., Xiao, X., Nichols, T. C., Bellinger, D. A., et al. (1998) Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther. 5, 40–49.

46.	Nakai, H., Storm, T. A., and Kay, M. A. (2000) Recruitment of single-strand recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J. Virol. 74, 9451–9463.

47.	Peel, A. L., Zolotukhin, S., Schrimsher, G. W., Muzyczla, N., and Reier, P. J. (1997) Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther. 4, 16–24.

48.	Ponnazhagan, S., Erikson, D., Kearns, W. G., Zhou, S. Z., Nahreini, P., Wang, X. S., et al. (1997) Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Hum. Gene Ther. 8, 275–284.

49.	Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., and Srivastava, A. (1999) Human fibroblast growth factor receptor 1 is a co-receptor for infection by adenoassociated virus 2. Nat. Med. 5, 71–77.

50.	Qing, K. Y., Wang, X.-S., Kube, D. M., Ponnazhagan, S., Bajpai, A., and Srivastava, A. (1997) Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. Proc. Natl. Acad. Sci. USA 94, 10,879–10,884.

51.	Richardson, W. D. and Westphal, H. (1981) A cascade of adenovirus early functions is required for expression of adeno-associated virus. Cell 27, 133–141. <Occurrence Type="DOI"><Handle>10.1016/0092-8674(81)90367-6</Handle></Occurrence>

52.	Samulski, R. J., Chen, L. S., and Shenk, T. (1989) Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J. Virol. 63, 3822–3828.

53.	Samulski, R. J. and Shenk, T. (1988) Adenovirus E1B 55-Mr polypeptide facilitates timely cytoplasmic accumulation of adeno-associated virus mRNAs. J. Virol. 62, 206–210.

54.	Sanlioglu, S., Benson, P. K., Yang, J., Atkinson, E. M., Reynolds, T., and Engelhardt, J. F. (2000) Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by Rac1 and phosphatidylinositol-3 kinase activation. J. Virol. 74, 9184–9196.

55.	Srivasatva, A., Lusby, E., and Berns, K. I. (1983) Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol. 45, 555–564.

56.	Summerford, C., Bartlett, J. S., and Samulski, R. J. (1999) AlphaV Beta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5, 78–82.

57.	Summerford, C. and Samulski, R. J. (1998) Membrane-associated heparin sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438–1445.

58.	Tamayose, K., Hirai, Y., and Shimada, T. (1996) A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum. Gene Ther. 7, 507–513.

59.	Ward, P., F. B., D., O’Donnell, M. E., and Berns, K. I. (1998) Role of the adenovirus DNA-binding protein in in vitro adeno-associated virus DNA replication. J. Virol. 72, 420–427.

60.	West, M. H. P., Trempe, J. P., Tratschin, J.-D., and Carter, B. J. (1987) Gene expression in adeno-associated virus vectors: The effects of chimeric mRNA structure, helper virus and adenovirus VA1 RNA. Virology 160, 38–47. <Occurrence Type="DOI"><Handle>10.1016/0042-6822(87)90041-9</Handle></Occurrence>

61.	Xiao, W., Berta, S. C., Lu, M. M., Moscioni, A. D., Tazelaar, J., and Wilson, J. M. (1998) Adeno-associated virus as a vector for liver directed gene therapy. J. Virol. 72, 10,222–10,226.

62.	Xiao, W., Chirmule, n., Schnell, M. A., Tazelar, J., Hughes, J. V., and Wilson, J. M. (2000) Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol. Ther. 1, 323–329.

63.	Xiao, X., Li, J., and Samulski, R. J. (1996) Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70, 8098–8108.

64.	Xiao, X., Li, J., and Samulski, R. J. (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224–2232.

65.	Yan, Z., Zhang, Y., Duan, D., and Engelhardt, J. F. (2000) Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc. Natl. Acad. Sci. USA 97, 6716–6721.

66.	Yang, J., Zhou, W., Zhang, Y., Zidon, T., Ritchie, T., and Engelhardt, J. F. (1999) Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J. Virol. 73, 9468–9477.

67.	Zeitlin, P. L., Chu, S., Conrad, C., McVeigh, U., Ferguson, K., Flotte, T. R., et al. (1995) Alveolar stem cell transduction by an adeno-associated viral vector. Gene Ther. 2, 623–631.

68.	Zhang, Y., Chirmule, N., Gao, G.-P., and Wilson, J. (2000) CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J. Virol. 74, 8003–8010.

69.	Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., et al. (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973–985.

70.	Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., et al. (1989) Current Protocols in Molecular Biology, vol. 1, Wiley, New York.

71.	Bartlett, J. S. and Samulski, R. J. (1996): Methods for the construction and propaga-tion of recombinant adeno-associated virus vectors, in Methods in Molecular Medicine, Gene Therapy Protocols (Robbins, P., ed.), Humana, Totowa, NJ, pp. 25–40.

Comments (Loading...)

Post comment/View all comments